Figure 3.

Summarizing results of pre‐ and posttest probabilities for evaluated clinical biomarkers in low‐ and high risk‐risk preoperative setting. Estimates based on pooled likelihood ratios (Table 2). Thickness of bars represents the number of studies performed on each marker; range, 2–20.

†, Based on prevalence of lymph node metastasis in patients preoperatively diagnosed with low‐grade (7%, left panel) and high‐grade endometrial cancer (20%, right panel), respectively.

Abbreviations: ¹⁸FDG PET‐CT, ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography; BMI, body mass index; Ca‐125, cancer antigen 125; CT, computed tomography; EC, endometrial carcinoma; MRI, magnetic resonance imaging.